Complete lecithin cholesterol acyltransferase (LCAT) deficiency is a rare genetic cause of extreme reduction in high density lipoproteins and there is a high prevalence of chronic renal dysfunction that may progress to renal failure. Previous in vitro studies suggest the vesicular lipoprotein X (LpX) particles commonly seen in LCAT-deficient plasmas may be causative. To test this hypothesis, we have generated a novel murine model that selectively accumulate LpX in the circulation by cross breeding the sterol regulatory element binding protein (SREBP) 1a transgenic mice (S؉) with the LCAT knockout (lcat؊/؊) mice. Lecithin cholesterol acyltransferase (LCAT) deficiency is a rare monogenic disorder causative of severe plasma high density lipoprotein (HDL) deficiency. It has been well established that LCAT mediates the transfer of the sn-2 fatty acyl moiety in phosphatidylcholine (PC) to the hydroxyl group of cholesterol. This reaction occurs predominantly on the HDL particles but significant LCAT activity has also been documented in non-HDL lipoprotein particles. 1,2 This reaction is central to the reverse cholesterol transport pathway in HDL metabolism 3 and a deficiency of the enzyme activity results in a reduction in plasma HDL-cholesterol (HDL-C) levels in a concentration-dependent manner. The residual plasma HDL is characterized by an accumulation of disk-shaped pre HDL that may form the characteristic rouleaux on electron microscopy. 4,5 Other lipid phenotypes include an increase in plasma free cholesterol to esterified cholesterol (FC/CE) ratio, modest fasting hypertriglyceridemia, morphologically abnormal low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles and the formation of FC-and phospholipid (PL)-rich but triglyceride-poor vesicles known as lipoprotein X (LpX). 4,6 These vesicles, with the buoyant density in the LDL range but